| 1393 |
National Cancer Institute |
Html |
en |
Cancer-Related Post-traumatic Stress (PDQ®)–Health Professional Version |
Expert-reviewed information summary about post-traumatic stress and related symptoms in cancer patients, cancer survivors, and their family members. Assessment and treatment of these symptoms are discussed. |
| traumatic event | 0.311819 |
| cancer treatment | 0.301201 |
| post-traumatic stress disorder | 0.298884 |
| study | 0.281873 |
| full-criteria PTSD group | 0.329802 |
| PTSD trauma model | 0.338033 |
| PTSD criteria | 0.318826 |
| cancer experience | 0.272753 |
| cancer treatment received. | 0.271124 |
| intrusive thoughts | 0.407892 |
| PTSD Checklist-Civilian Version | 0.325724 |
| broad PTSD symptom | 0.316477 |
| PTSD trauma | 0.338289 |
| specific PTS symptoms | 0.273748 |
| PTSD immediately postsurgery | 0.349332 |
| PTSD symptoms | 0.490814 |
| current PTSD | 0.319607 |
| early-stage breast cancer | 0.412505 |
| adult cancer patients | 0.298142 |
| child cancer survivors | 0.27606 |
| PTS symptoms | 0.347359 |
| diagnostic criteria | 0.511308 |
| PTSD patients | 0.326115 |
|
| bone marrow transplant | 0.330974 |
| mild-to-moderate cancer-related PTSD | 0.358971 |
| structured clinical interview | 0.302585 |
| PTSD-like symptoms | 0.416348 |
| patients | 0.448951 |
| cancer patients | 0.334316 |
| post-traumatic symptoms | 0.263192 |
| PTSD diagnostic criterion | 0.407584 |
| breast cancer | 0.98286 |
| DSM-IV PTSD syndrome | 0.373544 |
| breast cancer survivors | 0.33396 |
| acute stress disorder | 0.277841 |
| lifetime PTSD | 0.33232 |
| PTSD | 0.797398 |
| symptoms | 0.617748 |
| DSM-IV PTSD | 0.41474 |
| PTSD module | 0.291206 |
| cancer survivors | 0.345932 |
| stress symptoms | 0.286797 |
| metastatic breast cancer | 0.268733 |
| precise PTSD symptoms | 0.406493 |
| DSM-IV diagnostic criteria | 0.337351 |
| early-stage cancer | 0.260629 |
|
CLICK HERE |
| 1643 |
National Cancer Institute |
Html |
en |
Mistletoe Extracts (PDQ®)–Patient Version |
Mistletoe extracts have been studied in Europe as a treatment for many illness including cancer. Read about the use of mistletoe therapy in cancer patients and the results of clinical trials in this expert-reviewed summary. |
| cancer treatment | 0.498733 |
| mistletoe extracts | 0.84177 |
| European mistletoe species | 0.59742 |
| cancer cell growth | 0.480977 |
| Cancer Complementary | 0.499093 |
| white blood cells | 0.478127 |
| clinical trials | 0.814026 |
| injectable mistletoe extracts | 0.584449 |
| cancer information summary | 0.547122 |
| alternative cancer therapies | 0.496047 |
| National Center | 0.487589 |
| CAM cancer research | 0.482862 |
| mistletoe extract products | 0.586898 |
| patients | 0.558663 |
| cancer patients | 0.50887 |
| body fight cancer | 0.488697 |
| certain European countries | 0.486934 |
| mistletoe | 0.936372 |
| Integrative Health | 0.4867 |
| NCI PDQ cancer | 0.515414 |
| alternative medicine therapies | 0.509636 |
| cancer information database | 0.494234 |
| randomized clinical trials | 0.496538 |
| Therapies Editorial Board | 0.492111 |
|
| metastatic pancreatic cancer | 0.479516 |
| mistletoe plant | 0.574134 |
| injectable mistletoe | 0.604199 |
| treatment | 0.516928 |
| Complementary Therapies Editorial | 0.512225 |
| human cancer cells | 0.481784 |
| Drug Administration | 0.544399 |
| Cancer Information Specialist | 0.48946 |
| cancer cells | 0.492698 |
| PDQ cancer information | 0.630287 |
| Cancer Information Service | 0.543474 |
| mistletoe extract | 0.769423 |
| mistletoe dose | 0.56553 |
| treatment clinical trials | 0.481986 |
| National Cancer Institute | 0.675985 |
| studies | 0.476699 |
| alternative medicine | 0.586786 |
| European mistletoe | 0.657219 |
| mistletoe products | 0.583934 |
| mistletoe lectins | 0.572067 |
| cancer clinical trials | 0.506662 |
| cell lung cancer | 0.478767 |
| alternative therapies | 0.505915 |
| cancer information summaries | 0.526674 |
|
CLICK HERE |
| 1728 |
National Cancer Institute |
Html |
en |
End-of-Life Care for People Who Have Cancer |
A fact sheet that answers some of the questions patients, their family members, and caregivers may have about the end of life. |
| family members | 0.618911 |
| family caregivers | 0.218961 |
| advance directives | 0.30098 |
| patients | 0.4187 |
| people | 0.36964 |
| life | 0.365064 |
| caregivers | 0.584429 |
|
| health care team | 0.768547 |
| person | 0.99495 |
| patient | 0.848579 |
| hospice care | 0.29663 |
| Related Resources section | 0.284122 |
| loved ones | 0.266236 |
| cancer | 0.462571 |
|
CLICK HERE |
| 1819 |
National Cancer Institute |
Html |
es |
Tratamiento del tumor de Wilms y otros tumores renales infantiles (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento del tumor de Wilms y otros tumores renales infantiles. |
| wilms tumor | 0.821427 |
| wilms tumours | 0.50463 |
| anomalÃas congénitas | 0.435681 |
| gen blm | 0.427775 |
| gen oncoinhibidor | 0.442787 |
| gen oncosupresor h19 | 0.43309 |
| gen drosha | 0.426257 |
| anomalÃas cardÃacas congénitas | 0.422372 |
| Ahmed HU | 0.422578 |
| tumores renales | 0.459976 |
| gen ctr9 | 0.450784 |
| gen cdkn1c | 0.42907 |
| renal tumours | 0.428247 |
| afección gen fenotipo | 0.433197 |
| sÃndrome wagr | 0.961757 |
| gen pax6 | 0.452923 |
| Gen Wilms tumor | 0.633712 |
| cánceres renales | 0.430685 |
| sÃndrome congénito | 0.454197 |
| Wilms Tumor Study | 0.602512 |
| gen insulin growth | 0.431312 |
| complejos génicos | 0.423036 |
| anomalÃas renales | 0.500059 |
| gen nsd1 | 0.428186 |
| Beckwith-Wiedemann padecerán | 0.430165 |
|
| Wilms SÃndrome | 0.573396 |
| gen wt1 | 0.557769 |
| gen fbxw7 | 0.42494 |
| Lancet Oncol | 0.427372 |
| restos nefrógenos | 0.582325 |
| Spring Harbor Laboratory | 0.432622 |
| Cold Spring Harbor | 0.432647 |
| sÃndromes wagr | 0.42334 |
| gen ptch1 | 0.424282 |
| efectos tardÃos | 0.471463 |
| tumor wilms | 0.630299 |
| genes wt1 | 0.422664 |
| dominio iiib | 0.434344 |
| antecedentes familiares | 0.436654 |
| Wilms anaplásico difuso | 0.515326 |
| Wilms esporádico | 0.619115 |
| mutaciones interruptoras | 0.593507 |
| gen wtx | 0.481725 |
| monoparental paterna | 0.424225 |
| primary malignant non-wilms | 0.443665 |
| gen tp53 | 0.452138 |
| cánceres embrionarios.Las mutaciones | 0.471064 |
| insuficiencia renal | 0.449112 |
| células renales | 0.428025 |
|
CLICK HERE |
| 1885 |
National Cancer Institute |
Html |
es |
Tratamiento de los cánceres poco comunes en la niñez (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca del tratamiento de los cánceres poco comunes en la niñez como los cánceres de la cabeza y el cuello, el tórax, el abdomen, el aparato reproductor, la piel y otros. |
| Group Childhood Cancer | 0.303634 |
| Kadish Estadio Descripción | 0.300271 |
| cancer statistics | 0.326488 |
| pediatric rare tumors | 0.992234 |
| patients with relapsed | 0.372754 |
| cuadro clÃnico | 0.354432 |
| Advanced Solid Tumors | 0.370423 |
| estadificación posoperatoria | 0.711901 |
| GPOH Pediatric Rare | 0.343984 |
| cooperative study group | 0.363939 |
| Sin embargo | 0.560837 |
| ATA Task Force | 0.473736 |
| Pediatric Patients with | 0.461297 |
| Childhood Cancer Research | 0.442875 |
| cuáles pacientes | 0.308117 |
| Targeted Therapy Directed | 0.368386 |
| Treating Pediatric Patients | 0.460472 |
| or histiocytic disorders | 0.361605 |
| Internet ClinicalTrials.gov | 0.45578 |
| metástasis distantes | 0.307395 |
| Children's Oncology Group | 0.570172 |
| niños vs | 0.418573 |
| International Classification | 0.392171 |
| or refractory advanced | 0.367754 |
| tiroides medular nem2 | 0.365237 |
|
| very rare tumors | 0.299588 |
| Refractory Advanced Solid | 0.36854 |
| carcinoma nasofarÃngeo | 0.834137 |
| Pediatric Molecular Analysis | 0.447293 |
| Pediatric MATCH | 0.923242 |
| pediatric thyroid cancer | 0.456559 |
| End Results | 0.382399 |
| gammagrafÃa ósea | 0.326636 |
| BRAF V600E | 0.354329 |
| Childhood Cancer | 0.803535 |
| relapsed or refractory | 0.373353 |
| efectos tardÃos | 0.368787 |
| ATA Pediatric Risk | 0.307191 |
| menudo metástasis | 0.316315 |
| Riesgo pediátrico intermedio | 0.363674 |
| rare pediatric tumors | 0.355894 |
| PDQ Tratamiento | 0.348659 |
| mutaciones braf v600e | 0.349145 |
| NCI-COG Pediatric Molecular | 0.449773 |
| gammagrafÃa diagnóstica | 0.608069 |
| Clin Oncol | 0.421865 |
| subgrupo xi | 0.374046 |
| with relapsed or | 0.368469 |
| european cooperative study | 0.370036 |
|
CLICK HERE |
| 2032 |
National Cancer Institute |
Html |
es |
Exámenes de detección del cáncer de próstata (PDQ®)–Versión para profesionales de salud |
Resumen de información revisada por expertos acerca de las pruebas utilizadas para detectar el cáncer de próstata. |
| or watchful waiting | 0.527761 |
| Prostate Cancer Group-4 | 0.536467 |
| Koyama T | 0.514342 |
| estudio erspc | 0.525762 |
| Sin embargo | 0.633101 |
| Resnick MJ | 0.514745 |
| paÃses cuáles factores | 0.523397 |
| detección versus | 0.572904 |
| Holmberg L | 0.514356 |
| ensayo plco | 0.516954 |
| Swedish Cancer Registry | 0.524495 |
| Ahmed HU | 0.514521 |
| jurisdicciones europeas colaboradoras | 0.519184 |
| Preventive Services Task | 0.58607 |
| Ovarian Cancer Screening | 0.580102 |
| consiguiente tratamiento | 0.524752 |
| Croswell JM | 0.515275 |
| estudio prostate testing | 0.532458 |
| Estados Unidos | 0.630717 |
| centro göteborg | 0.570246 |
| siguientes tasas | 0.517703 |
| Prostate Cancer Prevention | 0.525333 |
| PSA rutinarias | 0.626469 |
| FJ Jr | 0.514192 |
| evolución natural benigna | 0.523168 |
|
| centro sueco göteborg | 0.523946 |
| trascendencia clÃnica | 0.542862 |
| Lancet Oncol | 0.516366 |
| Eur Urol | 0.51628 |
| End Results | 0.514418 |
| Loeb S | 0.514034 |
| Scandinavian Prostate Cancer | 0.583772 |
| seguimiento diagnóstico | 0.518794 |
| Gen Intern Med | 0.526679 |
| lesiones prostáticas benignas | 0.525347 |
| radical prostatectomy | 0.520653 |
| PaÃses Bajos | 0.556513 |
| Fan KH | 0.51463 |
| edad promedio | 0.515679 |
| Chou R | 0.514768 |
| PDQ Tratamiento | 0.51809 |
| European Randomized Study | 0.573324 |
| Intern Med | 0.549412 |
| Steineck G | 0.514536 |
| Services Task Force | 0.584434 |
| prostate cancer | 0.738954 |
| datos probatorios | 0.915311 |
| Prostate Intervention Versus | 0.524636 |
| Cancer Screening Trial | 0.580497 |
|
CLICK HERE |
| 2055 |
National Cancer Institute |
Html |
es |
Obesidad y cáncer |
Hoja informativa que resume la evidencia que relaciona el sobrepeso y la obesidad al riesgo de cáncer. |
| body mass | 0.350143 |
| Cancer Research Fund | 0.305964 |
| Wang F | 0.302675 |
| IMC CategorÃa | 0.303709 |
| ligero aumento | 0.313291 |
| anthropometric factors | 0.304184 |
| pooled analysis from | 0.302634 |
| Wang X | 0.302352 |
| observational studies | 0.307777 |
| male breast | 0.30286 |
| risk factors | 0.317009 |
| Kitahara CM | 0.305306 |
| to modifiable factors | 0.302578 |
| ovarian cancer | 0.313319 |
| Estados Unidos | 0.306361 |
| mechanisms linking obesity | 0.302489 |
| PubMed Abstract | 0.981157 |
| Women's Health Initiative | 0.305794 |
| obesity prevalence among | 0.302851 |
| endometrial cancer | 0.302426 |
| Clinical Oncology | 0.31976 |
| obesidad causa | 0.307215 |
| prospective observational studies | 0.307481 |
| International Journal | 0.314669 |
| gallbladder cancer | 0.310353 |
|
| body size throughout | 0.303222 |
| United States | 0.304211 |
| Renehan AG | 0.302352 |
| Body Fatness | 0.302339 |
| mayores riesgos | 0.303903 |
| hormonal risk factors | 0.304977 |
| dose-response meta-analysis | 0.303474 |
| Cancer Research | 0.314608 |
| PLoS Medicine | 0.303294 |
| epidemiological studies | 0.304197 |
| Cancer Prevention Trial | 0.306279 |
| Current Oncology Reports | 0.302446 |
| different risk factors | 0.304931 |
| systematic review | 0.305695 |
| Annual Review | 0.302768 |
| risk according | 0.303418 |
| Excess body weight | 0.303071 |
| physical activity | 0.302433 |
| pooled analysis | 0.316054 |
| Cancer Institute | 0.315531 |
| lymphedema risk factors | 0.304822 |
| JAMA Oncology | 0.304192 |
| prospective studies | 0.331726 |
| New England Journal | 0.306423 |
|
CLICK HERE |
| 3599 |
National Cancer Institute |
Html |
en |
The RAS Initiative |
NCI established the RAS Initiative to explore innovative approaches for attacking the proteins encoded by mutant forms of RAS genes and to ultimately create effective, new therapies for RAS-related cancers. |
| new therapies | 0.393067 |
| RAS | 0.99043 |
| RAS family | 0.739708 |
| long way | 0.387894 |
| oncogenic RAS | 0.6688 |
| primary focus | 0.382845 |
| RAS problem | 0.663793 |
| industry | 0.314692 |
| videos | 0.313651 |
| mouse retroviruses | 0.388906 |
| lab | 0.314136 |
| percent | 0.362189 |
| online forum RAS | 0.726513 |
| RAS reagents | 0.661904 |
| Douglas R. Lowy | 0.440325 |
| RAS genes | 0.803577 |
| Varmus’s vision | 0.381489 |
| RAS hub | 0.667188 |
| entire field | 0.379292 |
| mutations | 0.318554 |
| RAS oncogenes | 0.710337 |
| proteins | 0.316387 |
| Dear Colleagues | 0.397967 |
| National Cancer Institute | 0.440589 |
|
| pancreatic cancers | 0.432526 |
| NCI director | 0.401396 |
| RAS-related cancers | 0.425588 |
| events | 0.31366 |
| group | 0.314948 |
| innovative approaches | 0.393563 |
| goal | 0.328772 |
| biology | 0.314898 |
| academic researchers | 0.385896 |
| RAS Central | 0.733488 |
| virtual network | 0.380109 |
| headway | 0.320561 |
| Dr. Harold Varmus | 0.45561 |
| blog posts | 0.37846 |
| ras initiative | 0.905093 |
| mutant forms | 0.396413 |
| scientists | 0.313674 |
| useful tools | 0.379773 |
| human cancers | 0.42887 |
| fascinating problem | 0.378178 |
| colorectal cancers | 0.432751 |
| concerted effort | 0.392419 |
| time | 0.314762 |
|
CLICK HERE |
| 16696 |
National Cancer Institute |
Html |
en |
Understanding Cervical Changes: A Health Guide for Women |
Explains abnormal Pap test, HPV test, and Pap/HPV cotest results. Treatment and follow-up care for abnormal cervical cancer screening results including ASC-US, AGC, LSIL, ASC-H, HSIL, AIS. Learn about colposcopy, types of biopsies, CIN, and HPV vaccine. |
| cervical screening test | 0.296143 |
| cervical cancer cells | 0.337703 |
| health care provider | 0.931179 |
| cause cervical cancer | 0.303315 |
| abnormal cervical changes | 0.298611 |
| HPV types | 0.331542 |
| hpv infections | 0.33479 |
| abnormal cervical cell | 0.295805 |
| different HPV test | 0.298266 |
| cervical screening tests | 0.300727 |
| cervical cells | 0.440061 |
| HPV test work | 0.298659 |
| test results | 0.460749 |
| abnormal cervical screening | 0.340129 |
| HPV test | 0.548179 |
| cervical cancer screening | 0.419584 |
| HPV test result | 0.334901 |
| pap test | 0.669223 |
| cervical cancer | 0.659605 |
| abnormal test result | 0.292044 |
| high-risk hpv types | 0.317446 |
| HPV test results | 0.312992 |
| high-risk HPV infection | 0.300301 |
| women | 0.2963 |
|
| treatment | 0.297209 |
| abnormal cervical cells | 0.352195 |
| HPV vaccination | 0.281435 |
| Follow-Up Testing section | 0.335149 |
| HPV vaccine | 0.303379 |
| routine HPV testing | 0.291048 |
| HPV | 0.555747 |
| Pap test result | 0.316098 |
| Low-risk HPV types | 0.299422 |
| cervical cell changes | 0.36625 |
| Cervical screening recommendations | 0.28727 |
| abnormal pap test | 0.394575 |
| abnormal cervical cancer | 0.33209 |
| HPV vaccine series | 0.282155 |
| Normal Pap test | 0.282878 |
| Unsatisfactory Pap test | 0.281328 |
| Possible next steps | 0.307487 |
| common abnormal Pap | 0.287706 |
| HPV tests | 0.293108 |
| pap test results | 0.389844 |
| HPV infection | 0.355986 |
| abnormal cervical tissue | 0.293862 |
| recent abnormal Pap | 0.289466 |
| Cervical Cancer Treatment | 0.291973 |
|
CLICK HERE |
| 17287 |
National Cancer Institute |
Html |
es |
Búsqueda de servicios médicos |
Sugerencias para elegir a un doctor o un establecimiento de tratamiento, opciones de cuidados médicos, atención a domicilio y cuidados para pacientes terminales. |
| teléfono al ACoS | 0.406963 |
| practicantes miembros | 0.405783 |
| lÃnea quality check | 0.40869 |
| es el doctor | 0.42878 |
| Asociación Estadounidense | 0.423296 |
| usa rayos | 0.406918 |
| cirujanos miembros | 0.406162 |
| cuenta los costos | 0.406987 |
| capacitación de residencia | 0.407585 |
| Atención Médica Asequible | 0.412098 |
| Especialistas Médicos | 0.407972 |
| la asociación médica estadounidense | 0.414538 |
| información sobre cobertura | 0.405498 |
| International Cancer Control | 0.40739 |
|
| Colegio Estadounidense | 0.438106 |
| seguro médico | 0.61246 |
| Seguros Médicos | 0.413052 |
| OncologÃa ClÃnica | 0.406552 |
| pagar el tratamiento | 0.41398 |
| paciente satisface los requisitos | 0.408803 |
| Comisión Conjunta | 0.429316 |
| Oncólogo radiólogo | 0.407999 |
| los estados unidos | 0.40683 |
| atención médica | 0.448896 |
| Estados Unidos | 0.919617 |
| información a disposición | 0.40585 |
| cuestiones de viaje | 0.405374 |
|
CLICK HERE |